Skip to main content
. 2021 Jul 24;46:102079. doi: 10.1016/j.redox.2021.102079

Fig. 3.

Fig. 3

BRG1-dependent hepatocyte-derived CCL7 promotes macrophage migration. (A) HepG2 cells were transfected with siRNA targeting BRG1 or scrambled siRNA (SCR) followed by treatment with LPS for 6 h. Conditioned media were collected and chemotaxis assay was performed as described in Methods. (B) HepG2 cells were transfected with siRNA targeting BRG1 or scrambled siRNA (SCR) followed by treatment with palmitate for 12 h. Conditioned media were collected and chemotaxis assay was performed as described in Methods. (C) Primary hepatocytes were isolated from WT or LKO mice and treated with or without LPS for 6 h. Conditioned media were collected and chemotaxis assay was performed as described in Methods. (D) Primary hepatocytes were isolated from WT or LKO mice and treated with palmitate for 12 h. Conditioned media were collected and chemotaxis assay was performed as described in Methods. (E) HepG2 cells were infected with BRG1 adenovirus (Ad-BRG1) or the control adenovirus (Ad-GFP) followed by treatment with LPS for 6 h. Conditioned media were collected and chemotaxis assay was performed in the presence or absence of a CCL7-neutralizing antibody. (F) HepG2 cells were infected with BRG1 adenovirus (Ad-BRG1) or the control adenovirus (Ad-GFP) followed by treatment with palmitate for 12 h. Conditioned media were collected and chemotaxis assay was performed in the presence or absence of a CCL7-neutralizing antibody. (G) Primary hepatocytes were infected with BRG1 adenovirus (Ad-BRG1) or the control adenovirus (Ad-GFP) followed by treatment with LPS for 6 h. Conditioned media were collected and chemotaxis assay was performed in the presence or absence of a CCL7-neutralizing antibody. (H) Primary hepatocytes were infected with BRG1 adenovirus (Ad-BRG1) or the control adenovirus (Ad-GFP) followed by treatment with palmitate for 12 h. Conditioned media were collected and chemotaxis assay was performed in the presence or absence of a CCL7-neutralizing antibody.